drugset / Trial / NCT02592538

Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma

NCT02592538

Completed 66 enrolled First People's Hospital of Hangzhou
RandomizedParallel-groupOpen-labelTreatment

Summary

Endobiliary radiofrequency ablation (RFA) with biliary stent has been reported to be a beneficial treatment option for palliation of malignant biliary strictures. RFA uses a high-frequency alternating current to generate heat and achieve coagulative necrosis when in contact with tissue. Within the bile duct, RFA appears to be safe and may result in decreased tumor ingrowth. However, most of therapeutic effects were expected to delay bile duct obstruction rather than to decrease the tumor. Recently orally available chemotherapeutic agent, S-1, an oral fluoropyrimidine, was reported as effective in patients with bile duct adenocarcinoma. To date, little is known about the role of the addition of systemic chemotherapy to RFA for cholangiocarcinoma. The aim of this study is to evaluate the combined effect of RFA and S-1 in patients with unresectable cholangiocarcinoma.

Timeline

Start
2015-12
Primary completion
2018-08
Completion
2019-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject S-1 Small molecule 80 mg Oral
Subject S-1 Small molecule 100 mg Oral
Subject S-1 Small molecule 120 mg Oral

Indications